Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 13/20 | 0.62 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | RET | P07949 | 1/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.53 |
| ▸ | KIT | P10721 | 1/20 | 0.53 |
| ▸ | SRC | P12931 | 1/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.53 |
| ▸ | FLT1 | P17948 | 1/20 | 0.53 |
| ▸ | FLT4 | P35916 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | FRK | P42685 | 1/20 | 0.53 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.53 |
| ▸ | LDHA | P00338 | 1/20 | 0.52 |
| ▸ | LDHB | P07195 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1678955 | 1.00 | CSF1R (0.62) | CSF1RCDK2RETPDGFRBKIT | |
| SCHEMBL1679576 | 1.00 | CSF1R (0.62) | CSF1RCDK2RETPDGFRBKIT | |
| SCHEMBL1679263 | 0.86 | CSF1R (0.59) | CSF1RCDK2RETPDGFRBKIT | |
| SCHEMBL13313087 | 0.84 | AURKA (0.52) | CSF1RRETPDGFRBKITSRC | |
| SCHEMBL3557473 | 0.84 | AURKA (0.52) | CSF1RRETPDGFRBKITSRC | |
| SCHEMBL6528042 | 0.84 | CSF1R (0.53) | CSF1RCDK2RETPDGFRBKIT | |
| SCHEMBL3515072 | 0.84 | AURKA (0.52) | CSF1RRETPDGFRBKITSRC | |
| SCHEMBL3149272 | 0.84 | CSF1R (0.53) | CSF1RCDK2RETPDGFRBKIT | |
| SCHEMBL14705857 | 0.84 | CSF1R (0.48) | CSF1RCDK2RETPDGFRBKIT | |
| SCHEMBL13478835 | 0.84 | CSF1R (0.48) | CSF1RCDK2RETPDGFRBKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| EP-2516436-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | disclosed |
| EP-2338888-A1 | Imidazopyridine derivatives as JAK inhibitors | Almirall, S.A. (ES) | 2011-06-29 | — | — | EP | disclosed |
| US-20100331315-A1 | RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-12-30 | — | — | US | disclosed |
| EP-1363702-A4 | METHODS OF INHIBITING KINASES | CYTOPIA PTY LTD (AU) | 2007-08-22 | — | — | EP | disclosed |
| US-20060069084-A1 | Methods of inhibiting kinases | CYTOPIA RESEARCH PTY LTD (AU) | 2006-03-30 | — | — | US | disclosed |
| WO-2005033129-A1 | ANTIBACTERIAL AMIDE MACROCYCLES | BAYER HEALTHCARE AG (DE) | 2005-04-14 | — | — | WO | disclosed |
| EP-1511742-A1 | KINASE INHIBITORS | Cytopia PTY Ltd (AU) | 2005-03-09 | — | — | EP | disclosed |
| US-20040102455-A1 | Method of inhibiting kinases | CYTOPIA RESEARCH PTY LTD (AU) | 2004-05-27 | — | — | US | disclosed |
| WO-2003099811-A1 | KINASE INHIBITORS | CYTOPIA PTY LTD (AU) | 2003-12-04 | — | — | WO | disclosed |
| EP-1363702-A1 | METHODS OF INHIBITING KINASES | Cytopia PTY Ltd (AU) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002060492-A1 | METHODS OF INHIBITING KINASES | CYTOPIA PTY LTD (AU) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102455-A1 | Method of inhibiting kinases | JAK2, JAK1, JAK3 | CSF1R 1201/4885CDK2 58/4885RET 492/4885 |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | CSF1R 369/4885CDK2 65/4885RET 280/4885 |
| US-20100331315-A1 | RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | PIM2, PIM1, CDK2 | CSF1R 1108/4885CDK2 3/4885RET 210/4885 |
| US-20060069084-A1 | Methods of inhibiting kinases | JAK2, JAK1, JAK3 | CSF1R 1221/4885CDK2 55/4885RET 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.